Get the Daily Brief
Latest Biotech News
Advancements in Cell Therapy Manufacturing: Cellares Unveils Automated Quality Control Platform
Cellares announced strategic partnerships aimed at expanding capabilities of its Cell Q platform, an automated, high-throughput quality control system designed to meet commercial-scale cell...
Potential Biomarker and Therapeutic Advances in Pancreatic Cancer via HSAT Sugar Modulation
Researchers at the Salk Institute and UC San Diego have identified a cell surface sugar, antithrombin-binding heparan sulfate (HSAT), as a promising therapeutic target in pancreatic ductal...
FDA Panel Debates and Delays Critical Votes on Childhood Vaccine Recommendations
The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP), recently reconstituted under Health and Human Services Secretary Robert F. Kennedy Jr.,...
Bispecific Antibody Startup Dualitas Raises $65 Million to Advance Immune Modulation Therapies
Dualitas Therapeutics has secured $65 million in Series A funding to develop bispecific antibodies targeting two cell surface proteins on the same immune cell, leveraging proximity biology for...
Multiple Biotech IPOs Signal Renewed Investor Interest Amidst Market Uncertainty
Biopharmaceutical companies such as LB Pharmaceuticals have successfully raised significant capital via initial public offerings (IPOs) this September, with LB Pharma securing $285 million to...
Roche’s $3.5B Acquisition of 89bio Advances MASH Drug Development
Roche has agreed to acquire biotech company 89bio in a deal valued up to $3.5 billion, including upfront and contingent milestone payments. The acquisition centers on pegozafermin, an FGF21...
CDC Vaccine Advisory Panel Alters Childhood Immunization Guidelines
The U.S. CDC’s Advisory Committee on Immunization Practices (ACIP), reconstituted under Health and Human Services Secretary Robert F. Kennedy Jr., voted to revise vaccine recommendations. The...
LB Pharma Raises $285M IPO to Fund Schizophrenia Trial
New York-based biopharma LB Pharmaceuticals raised $285 million in an initial public offering to support a Phase III trial of LB-102, an oral benzamide antipsychotic candidate designed for...
Dual AI-Integrated Gene Therapy Platforms Forge High-Value Partnerships
Shape Therapeutics and VectorY Therapeutics announced a collaboration giving VectorY exclusive options to evaluate Shape's deep brain-penetrating AAV capsid technology, SHP-DB1, against multiple...
Advances in CRISPR and RNA Base Editing for Safer Gene Therapy
Researchers from UC San Diego and Yale have developed and highlighted small nuclear RNA base editing as a safer alternative to traditional CRISPR-Cas9 gene editing, addressing concerns of...
AI Model Predicts Risk of Over 1,000 Diseases Simultaneously
A novel generative AI model trained on data from the UK Biobank can forecast individual risk and timing of developing 1,258 diseases up to 20 years in advance. By integrating medical history with...
Breakthrough in Cancer Research: Targeting Pancreatic and Glioblastoma Tumors
Multiple studies unveiled novel molecular targets and mechanisms offering hope in combating lethal cancers. Indiana University researchers identified two proteins critical to pancreatic cancer's...
Emerging Biotech Startups Backed by Major Investors and Innovation Awards
New venture funds and leading startups are shaping the future of biotechnology. T.Rx Capital, co-founded by biotech veteran Robert Langer's son, announced a $77.5 million inaugural fund to invest...
Novel Therapies and Clinical Trial Updates in Metabolic and Autoimmune Diseases
Several early-stage therapeutic candidates and clinical results signal advances against obesity, diabetes, and autoimmune disorders. Hanmi Holdings presented preclinical data on HM-15275, a...
Advances in Imaging and Diagnostic Technologies
Innovative imaging and diagnostic tools continue to transform precision medicine. The Journal of Nuclear Medicine released cutting-edge molecular imaging studies that improve diagnostic accuracy....
Roche's $3.5B Bet on MASH Therapy 89bio
Roche has agreed to acquire 89bio in a deal totaling up to $3.5 billion, gaining access to pegozafermin, a phase 3-stage FGF21 analogue targeting metabolic dysfunction-associated steatohepatitis...
CDC Vaccine Panel Shifts Recommendations Under RFK Jr.
The CDC’s Advisory Committee on Immunization Practices (ACIP), reconstituted by Health Secretary Robert F. Kennedy Jr., voted to recommend that individuals 6 months and older should consult...
New CRISPR-Based and Genetic Editing Advances
Researchers from UC San Diego and Yale have developed safer genome editing technologies including small nuclear RNA base editing, an alternative to traditional CRISPR, which reduces unintended...
Advances in AI-Driven Biomedical Prediction and Diagnostics
A novel AI model trained on UK Biobank data can simultaneously forecast the risk of developing more than 1,000 diseases up to 20 years ahead, enabling comprehensive personalized risk prediction....
Novel Cancer Therapies and Biomarker Discoveries
Recent breakthroughs spotlight new therapeutic candidates and biomarkers in oncology. Regeneron reported a 100% response rate in a small smoldering multiple myeloma trial with its T-cell engager...